Research Gaps on Use of Opioids for Chronic Noncancer Pain: Findings From a Review of the Evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guideline

Journal of Pain

Volumn 10, Issue 2, 2009, Pages

  Chou, Roger ^a   Ballantyne, Jane C ^b   Fanciullo, Gilbert J ^c   Fine, Perry G ^d   Miaskowski, Christine ^e  

^a Oregon Evidence based Practice Center   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Analgesics; drug monitoring; evidence based medicine; harms; opioid; pain; research gaps; risk assessment; systematic review; treatment outcomes

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; METHADONE; MORPHINE; NALTREXONAZINE; PLACEBO; TRAMADOL;

CHRONIC PAIN; COCHRANE LIBRARY; CONSTIPATION; DRIVING ABILITY; DRUG ABUSE; DRUG DEPENDENCE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG MONITORING; DRUG WITHDRAWAL; ENDOCRINE DISEASE; GASTROINTESTINAL DISEASE; HEALTH CARE POLICY; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPERALGESIA; HYPOGONADISM; INFORMED CONSENT; LONG TERM CARE; LOW DRUG DOSE; MEDLINE; NAUSEA; PATIENT SAFETY; PREGNANCY; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMNOLENCE;

EID: 58949098585     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2008.10.007     Document Type: Review

References (144)

1. Ackerman S.J., Knight T., Schein J., Carter C., and Staats P. Risk of constipation in patients prescribed fentanyl transdermal system or oxycodone hydrochloride controlled-release in a California Medicaid population. Consult Pharm 19 (2004) 118-132
2. Adams L.L., Gatchel R.J., Robinson R.C., Polatin P., Gajraj N., Deschner M., and Noe C. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage 27 (2004) 440-459
3. Akbik H., Butler S.F., Budman S.H., Fernandez K., Katz N.P., and Jamison R.N. Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Symptom Manage 32 (2006) 287-293
4. Allan L., Richarz U., Simpson K., and Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine 30 (2005) 2484-2490
5. Angst M.S., and Clark J.D. Opioid-induced hyperalgesia: A qualitative systematic review. Anesthesiology 104 (2006) 570-587
6. Atluri S.L., and Sudarshan G. Development of a screening tool to detect the risk of inappropriate prescription opioid use in patients with chronic pain. Pain Physician 7 (2004) 333-338
7. Attal N., Guirimand F., Brasseur L., Gaude V., Chauvin M., and Bouhassira D. Effects of IV morphine in central pain: A randomized placebo-controlled study. Neurology 58 (2002) 554-563
8. Babul N., Provencher L., Laberge F., Harsanyi Z., and Moulin D. Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. J Clin Pharmacol 38 (1998) 74-81
9. Ballantyne J.C., and Mao J. Opioid therapy for chronic pain. N Engl J Med 349 (2003) 1943-1953
10. Beaver W.T., Wallenstein S.L., Houde R.W., and Rogers A. A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly, and of orally and parenterally administered methadone. Clin Pharmacol Ther 8 (1967) 415-426
11. Beaver W.T., Wallenstein S.L., Houde R.W., and Rogers A. A clinical comparison of the effects of oral and intramuscular administration of analgesics: pentazocine and phenazocine. Clin Pharmacol Ther 9 (1968) 582-597
12. Becker G., Galandi D., and Blum H.E. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: A systematic review. J Pain Symptom Manage 34 (2007) 547-565
13. Belgrade M.J., Schamber C.D., and Lindgren B.R. The DIRE score: Predicting outcomes of opioid prescribing for chronic pain. J Pain 7 (2006) 671-681
14. Bombardier C., Esmail R., and Nachemson A.L. the Back Review Group Editorial Board: The Cochrane Collaboration Back Review Group of Spinal Disorders. Spine 22 (1997) 837-840
15. Bouter L.M., Pennick V., and Bombardier C. the Editorial Board of the Back Review Group: Cochrane Back Review Group. Spine 28 (2003) 1215-1218
16. British Pain Society. Recommendations for the Appropriate Use of Opioids for Persistent Non-cancer Pain (the first revised edition) (March 2005), The British Pain Society, London
17. Butler S.F., Budman S.H., Fernandez K., and Jamison R.N. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 112 (2004) 65-75
18. Butler S.F., Budman S.H., Fernandez K.C., Houle B., Benoit C., Katz N., and Jamison R.N. Development and validation of the Current Opioid Misuse Measure. Pain 130 (2007) 144-156
19. Butler S.F., Fernandez K., Benoit C., Budman S.H., and Jamison R.N. Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R). J Pain 9 (2008) 360-372
20. Byas-Smith M.G., Chapman S.L., Reed B., and Cotsonis G. The effect of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain 21 (2005) 345-352
21. Caudill-Slosberg M.A., Schwartz L.M., and Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs 2000. Pain 109 (2004) 514-519
22. Center for Substance Abuse Treatment. Methadone-associated mortality: Report of a national assessment. May 2003
23. Office of Applied Studies, Substance Abuse and Mental Health Service Administration. Results from the 2004 National Survey on Drug Use and Health (2005), Department of Health and Human Services, Rockville, MD
24. Centers for Disease Control and Prevention: Unintentional poisoning deaths-United States, 1999-2004. Morb Mortal Wkly Rep 56 (2007) 93-96
25. Cepeda M.S., Camargo F., Zea C., and Valencia L. Tramadol for osteoarthritis. Cochrane Database Syst Rev (2006) CD005522
26. Chou R., Clark E., and Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: A systematic review. J Pain Symptom Manage 26 (2003) 1026-1048
27. Chou R., Fanciullo G., Fine P.G., Miaskowski C., Passik S., and Portenoy P. Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 10 (2009) 131-146
28. Chou R., and Huffman L. The use of opioids for chronic non-cancer pain: Evidence review. American Pain Society (2009) (in press)
29. Chugh S.S., Socoteanu C., Reinier K., Waltz J., Jui J., and Gunson K. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med 121 (2008) 66-71
30. Clark A.J., Ahmedzai S.H., Allan L.G., Camacho F., Horbay G.L., Richarz U., and Simpson K. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 20 (2004) 1419-1428
31. Compton P., Darakjian J., and Miotto K. Screening for addiction in patients with chronic pain and "problematic" substance use: Evaluation of a pilot assessment tool. J Pain Symptom Manage 16 (1998) 355-363
32. Corey D.T. A limited functional restoration program for injured workers: A randomised trial. J Occup Rehabil 6 (1996) 239-249
33. Cowan D.T., Wilson-Barnett J., Griffiths P., Vaughan D.J., Gondhia A., and Allan L.G. A randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of long-term opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine. Pain Med 6 (2005) 113-121
34. Cruciani R.A., Sekine R., Homel P., Lussier D., Yap Y., Suzuki Y., Schweitzer P., Yancovitz S.R., Lapin J.A., Shaiova L., Sheu R.G., and Portenoy R.K. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 29 (2005) 385-391
35. Daniell H.W. DHEAS deficiency during consumption of sustained-action prescribed opioids: Evidence for opioid-induced inhibition of adrenal androgen production. J Pain 7 (2006) 901-907
36. Daniell H.W. Hypogonadism in men consuming sustained-action oral opioids. J Pain 3 (2002) 377-384
37. Daniell H.W. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain 9 (2008) 28-36
38. De Conno F., Ripamonti C., Saita L., MacEachern T., Hanson J., and Bruera E. Role of rectal route in treating cancer pain: A randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol 13 (1995) 1004-1008
39. Dellemijn P.L., van Duijn H., and Vanneste J.A. Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage 16 (1998) 220-229
40. Deshpande A., Furlan A.D., Mailis-Gagnon A., Atlas S., and Turk D. Opioids for chronic low-back pain. Cochrane Database Syst Rev (2007) CD004959
41. Devulder J., Richarz U., and Nataraja S.H. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin 21 (2005) 1555-1568
42. Dunbar S.A., and Katz N.P. Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: Report of 20 cases. J Pain Symptom Manage 11 (1996) 163-171
43. Edwards R.R., Haythornthwaite J.A., Tella P., Max M.B., and Raja S. Basal heat pain thresholds predict opioid analgesia in patients with postherpetic neuralgia. Anesthesiology 104 (2006) 1243-1248
44. Eisenberg E., McNicol E.W., and Carr D.B. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: Systematic review and meta-analysis of randomized controlled trials. JAMA 293 (2005) 3043-3052
45. Fishbain D.A., Cutler R.B., Rosomoff H.L., and Rosomoff R.S. Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage 25 (2003) 559-577
46. Fishbain D.A., Cutler R.B., Rosomoff H.L., and Rosomoff R.S. Can patients taking opioids drive safely? A structured evidence-based review. J Pain Palliat Care Pharmacother 16 (2002) 9-28
47. Fishman S.M., Bandman T.B., Edwards A., and Borsook D. The opioid contract in the management of chronic pain. J Pain Symptom Manage 18 (1999) 27-37
48. Flor H., Fydrich T., and Turk D.C. Efficacy of multidisciplinary pain treatment centers: A meta-analytic review. Pain 49 (1992) 221-230
49. Franklin G.M., Mai J., Wickizer T., Turner J.A., Fulton-Kehoe D., and Grant L. Opioid dosing trends and mortality in Washington State workers' compensation, 1996-2002. Am J Ind Med 48 (2005) 91-99
50. Fredheim O.M., Kaasa S., Dale O., Klepstad P., Landro N.I., and Borchgrevink P.C. Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: A nine-month follow-up study. Palliat Med 20 (2006) 35-41
51. Freye E., Anderson-Hillemacher A., Ritzdorf I., and Levy J.V. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract 7 (2007) 123-129
52. Furlan A.D., Clarke J., Esmail R., Sinclair S., Irvin E., and Bombardier C. A critical review of reviews on the treatment of chronic low back pain. Spine 26 (2001) E155-E162
53. Furlan A.D., Sandoval J.A., Mailis-Gagnon A., and Tunks E. Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. CMAJ 174 (2006) 1589-1594
54. Gaertner J., Radbruch L., Giesecke T., Gerbershagen H., Petzke F., Ostgathe C., Elsner F., and Sabatowski R. Assessing cognition and psychomotor function under long-term treatment with controlled release oxycodone in non-cancer pain patients. Acta Anaesthesiol Scand 50 (2006) 664-672
55. Galski T., Williams J.B., and Ehle H.T. Effects of opioids on driving ability. J Pain Symptom Manage 19 (2000) 200-208
56. Gartlehner G., Hansen R.A., Nissman D., Lohr K.N., and Carey T.S. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol 59 (2006) 1040-1048
57. Graziotti P., and Goucke R. The use of oral opioids in patients with chronic nonmalignant pain: Management strategies. Med J Austr 167 (1997) 30-34
58. GSK, Adolor, London and Exton PU: GSK and Adolor announce preliminary results from phase 3 safety study of Alvimopan (Entereg/Entrareg). Available at: http://www.gsk.com/media/pressreleases/2007/2007_04_09_GSK1012.htm. Accessed April 9, 2007
59. Guzman J., Esmail R., Karjalainen K., Malmivaara A., Irvin E., and Bombardier C. Multidisciplinary rehabilitation for chronic low back pain: Systematic review. BMJ 322 (2001) 1511-1516
60. Hale M., Speight K., Harsanyi Z., Iwan T., Slagle N., Lacouture P., and Darke A. Efficacy of 12 hourly controlled-release codeine compared with as required dosing of acetaminophen plus codeine in patients with chronic low back pain. Pain Res Manag 2 (1997) 33-38
61. Hale M.E., Dvergsten C., and Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: Results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain 6 (2005) 21-28
62. Harris R.P., Helfand M., Woolf S.H., Lohr K.N., Mulrow C.D., Teutsch S.M., and Atkins D. Current methods of the third US Preventive Services Task Force. Am J Prev Med 20 (2001) 21-35
63. Hartung D.M., Middleton L., Haxby D.G., Koder M., Ketchum K.L., and Chou R. Rates of adverse events of long-acting opioids in a state Medicaid program. Ann Pharmacother 41 (2007) 921-928
64. Hays H. Use of methadone in treating chronic noncancer pain. Pain Res Manag 4 (1999) 23-27
65. Hoffman B.M., Chatkoff D.K., Papas R.K., and Kerns R.D. Meta-analysis of psychological interventions for chronic low back pain. Health Psychol 26 (2007) 1-9
66. Hojsted J., and Sjogren P. Addiction to opioids in chronic pain patients: A literature review. Eur J Pain 11 (2007) 490-518
67. Hollingshead J., Duhmke R., and Cornblath D. Tramadol for neuropathic pain. Cochrane Database Syst Rev (2006) CD003726
68. Holmes C.P., Gatchel R.J., Adams L.L., Stowell A.W., Hatten A., Noe C., and Lou L. An opioid screening instrument: Long-term evaluation of the utility of the Pain Medication Questionnaire. Pain Pract 6 (2006) 74-88
69. Huse E., Larbig W., Flor H., and Birbaumer N. The effect of opioids on phantom limb pain and cortical reorganization. Pain 90 (2001) 47-55
70. Jadad A.R., and McQuay H.J. Meta-analyses to evaluate analgesic interventions: A systematic qualitative review of their methodology. J Clin Epidemiol 49 (1996) 235-243
71. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., and McQuay H.J. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials 17 (1996) 1-12
72. Jamison R.N., Raymond S.A., Slawsby E.A., Nedeljkovic S.S., and Katz N.P. Opioid therapy for chronic noncancer back pain: A randomized prospective study. Spine 23 (1998) 2591-2600
73. Johnson M, Mortimer S, Bogle S, Hallam SJ. A study to compare subject acceptability of Duragesic with sustained release morphine in subjects requiring strong opioids for chronic non-malignant pain. Available at: http://www.janssen-cilag.com/content/backgrounders/janssen-cilag.com/Syn opsisFEN-GBR-21.pdf. Accessed May 29, 2007
74. Jovey R.D., Ennis J., Gardner-Nix J., Goldman B., Hays H., Lynch M., and Moulin D. Use of opioid analgesics for the treatment of chronic noncancer pain: A consensus statement and guidelines from the Canadian Pain Society, 2002. Pain Res Manag 8 (2003) 3A-28A
75. Kalso E., Allan L., Dellemijn P.L., Faura C.C., Ilias W.K., Jensen T.S., Perrot S., Plaghki L.H., and Zenz M. European Federation of Chapters of the International Association for the Study of Pain: Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 7 (2003) 381-386
76. Kalso E., Edwards J.E., Moore R.A., and McQuay H.J. Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain 112 (2004) 372-380
77. Kalso E., Simpson K.H., Slappendel R., Dejonckheere J., and Richarz U. Predicting long-term response to strong opioids in patients with low back pain: Findings from a randomized, controlled trial of transdermal fentanyl and morphine. BMC Med 5 (2007) 39
78. Karjalainen K., Malmivaara A., van Tulder M.W., Roine R., Jauhiainen M., Hurri H., and Koes B. Multidisciplinary biopsychosocial rehabilitation for subacute low back pain in working-age adults: A systematic review within the framework of the Cochrane Collaboration Back RevIew Group. Spine 26 (2001) 262-269
79. Krantz M.J., Lewkowiez L., Hays H., Woodroffe M.A., Robertson A.D., and Mehler P.S. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 137 (2002) 501-504
80. Lijmer J.G., Mol B.W., Heisterkamp S., Bonsel G.J., Prins M.H., van der Meulen J.H., and Bossuyt P.M. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 282 (1999) 1061-1066
81. Maier C., Hildebrandt J., Klinger R., Henrich-Eberl C., and Lindena G. Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain: Results of a double-blind placebo-controlled trial (MONTAS). Pain 97 (2002) 223-233
82. Manchikanti L., Pampati V., Damron K.S., and McManus C.D. Evaluation of variables in illicit drug use: does a controlled substance abuse screening tool identify illicit drug use?. Pain Physician 7 (2004) 71-75
83. Martell B. Systematic review: Opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 146 (2007) 116-127
84. Matsumoto A.K., Babul N., and Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: Results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med 6 (2005) 357-366
85. McCracken L.M., and Turk D.C. Behavioral and cognitive-behavioral treatment for chronic pain: Outcome, predictors of outcome, and treatment process. Spine 27 (2002) 2564-2573
86. McGinn T.G., Guyatt G.H., Wyer P.C., Naylor C.D., Stiell I.G., and Richardson W.S. Users' guides to the medical literature XXII: How to use articles about clinical decision rules. JAMA 284 (2000) 79-84
87. McNicol E., Horowicz-Mehler N., Fisk R.A., Bennett K., Gialeli-Goudas M., Chew P.W., Lau J., and Carr D. Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. J Pain 4 (2003) 231-256
88. McNicol E.D., Boyce D., Schumann R., and Carr D.B. Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev (2008) CD006332
89. Menefee L.A., Frank E.D., Crerand C., Jalali S., Park J., Sanschagrin K., and Besser M. The effects of transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions. Pain Med 5 (2004) 42-49
90. Mercadante S., Arcuri E., Fusco F., Tirelli W., Villari P., Bussolino C., Campa T., Conno F., and Ripamonti C. Randomized double-blind, double-dummy crossover clinical trial of oral tramadol versus rectal tramadol administration in opioid-naive cancer patients with pain. Support Care Cancer 13 (2005) 702-707
91. Mercadante S., and Portenoy R.K. Opioid poorly-responsive cancer pain, 1: Clinical considerations. J Pain Symptom Manage 21 (2001) 144-150
92. Michna E., Ross E.L., Hynes W.L., Nedeljkovic S.S., Soumekh S., Janfaza D., Palombi D., and Jamison R.N. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage 28 (2004) 250-258
93. Moher D., Pham B., Klassen T.P., Schulz K.F., Berlin J.A., Jadad A.R., and Liberati A. What contributions do languages other than English make on the results of meta-analyses?. J Clin Epidemiol 53 (2000) 964-972
94. Moore R.A., and McQuay H.J. Prevalence of opioid adverse events in chronic non-malignant pain: Systematic review of randomised trials of oral opioids. Arthritis Res Ther 7 (2005) R1046-R1051
95. Morley J.S., Bridson J., Nash T.P., Miles J.B., White S., and Makin M.K. Low-dose methadone has an analgesic effect in neuropathic pain: A double-blind randomized controlled crossover trial. Palliat Med 17 (2003) 576-587
96. Morley S., Eccleston C., and Williams A. Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain 80 (1999) 1-13
97. Nicholson B., Ross E., Weil A., Sasaki J., and Sacks G. Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules. Curr Med Res Opin 22 (2006) 539-550
98. Niemann T., Madsen L.G., Larsen S., and Thorsgaard N. Opioid treatment of painful chronic pancreatitis: Transdermal fentanyl versus sustained-release morphine. Int J Pancreatol 27 (2000) 235-240
99. Noble M., Tregear S.J., Treadwell J.R., and Schoelles K. Long-term opioid therapy for chronic noncancer pain: A systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage 35 (2008) 214-228
100. Olsen Y., Daumit G.L., and Ford D.E. Opioid prescriptions by US primary care physicians from 1992 to 2001. J Pain 7 (2006) 225-235
101. Oregon Department of Human Services. Methadone deaths (and distribution) on the rise. CD Summary 52 14 (2003)
102. Ostelo R.W., van Tulder M.W., Vlaeyen J.W., Linton S.J., Morley S.J., and Assendelft W.J. Behavioural treatment for chronic low-back pain. Cochrane Database of Syst Rev (2005) CD002014
103. Oxman A.D., and Guyatt G.H. Validation of an index of the quality of review articles. J Clin Epidemiol 44 (1991) 1271-1278
104. Paulson D.M., Kennedy D.T., Donovick R.A., Carpenter R.L., Cherubini M., Techner L., Du W., Ma Y., Schmidt W.K., Wallin B., and Jackson D. Alvimopan: An oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction-a 21-day treatment-randomized clinical trial. J Pain 6 (2005) 184-192
105. Peters J., Large R.G., and Elkind G. Follow-up results from a randomised controlled trial evaluating in- and outpatient pain management programmes. Pain 50 (1992) 41-50
106. Petrone D., Kamin M., and Olson W. Slowing the titration rate of tramadol HCl reduces the incidence of discontinuation due to nausea and/or vomiting: A double-blind randomized trial. J Clin Pharm Ther 24 (1999) 115-123
107. Portenoy R. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin 23 (2007) 223-233
108. Portenoy R., Farrar J., Backonja M., Cleeland C., Yang K., Friedman M., Colucci S., and Richards P. Long-term use of controlled-release oxycodone for noncancer pain: Results of a 3-year registry study. Clin J Pain 23 (2007) 287-299
109. Portenoy R.K., Thomas J., Boatwright M.L.M.B., Tran D., Galasso F.L., Stambler N., Von Gunten C.F., and Israel R.J. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: A double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 35 (2008) 458-468
110. Quang-Cantagrel N.D., Wallace M.S., and Magnuson S.K. Opioid substitution to improve the effectiveness of chronic noncancer pain control: A chart review. Anesth Analg 90 (2000) 933-937
111. Raja S.N., Haythornthwaite J.A., Pappagallo M., Clark M.R., Travison T.G., Sabeen S., Royall R.M., and Max M.B. Opioids versus antidepressants in postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 59 (2003) 1015-1021
112. Ralphs J.A., Williams A.C., Richardson P.H., Pither C.E., and Nicholas M.K. Opiate reduction in chronic pain patients: A comparison of patient-controlled reduction and staff controlled cocktail methods. Pain 56 (1994) 279-288
113. Rauck R.L. The ACTION study: A randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. J Opioid Manag 2 (2006) 155-166
114. Rauck R.L. A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-released tablets) for the treatment of chronic, moderate to severe low back pain: Improved physical functioning in the ACTION trial. J Opioid Manag 3 (2007) 35-43
115. Ruoff G.E. Slowing the initial titration rate of tramadol improves tolerability. Pharmacotherapy 19 (1999) 88-93
116. Sabatowski R., Schwalen S., Rettig K., Herberg K.W., Kasper S.M., and Radbruch L. Driving ability under long-term treatment with transdermal fentanyl. J Pain Symptom Manage 25 (2003) 38-47
117. Salzman R.T., and Brobyn R.D. Long-term comparison of suprofen and propoxyphene in patients with osteoarthritis. Pharmacology 27 Suppl 1 (1983) 55-64
118. Salzman R.T., Roberts M.S., Wild J., Fabian C., Reder R.F., and Goldenheim P.D. Can a controlled release oral dose form of oxycodone be used as readily as an immediate release form for the purpose of titrating to stable pain control?. J Pain Symptom Manage 18 (1999) 271-279
119. Sandoval J.A., Furlan A.D., and Mailis-Gagnon A. Oral methadone for chronic noncancer pain: A systematic literature review of reasons for administration, prescription patterns, effectiveness, and side effects. Clin J Pain 21 (2005) 503-512
120. Saper J.R., Lake III A.E., Hamel R.L., Lutz T.E., Branca B., Sims D.B., and Kroll M.M. Daily scheduled opioids for intractable head pain: Long-term observations of a treatment program. Neurology 62 (2004) 1687-1694
121. Schonstein E., Kenny D.T., Keating J., and Koes B.W. Work conditioning, work hardening and functional restoration for workers with back and neck pain. Cochrane Database Syst Rev (2003) CD001822
122. Sigler K. Effect of a triplicate prescription law on prescribing of Schedule II drugs. Am J Hosp Pharm 41 (1984) 108-111
123. Simpson D.M., Messina J., Xie F., and Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: A multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 29 (2007) 588-601
124. Staats P.S., Markowitz J., and Schein J. Incidence of constipation associated with long-acting opioid therapy: A comparative study. South Med J 97 (2004) 129-134
125. Stewart W.F., Ricci J.A., Chee E., Morganstein D., and Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 290 (2003) 2443-2454
126. Takkouche B., Montes-Martinez A., Gill S.S., and Etminam M. Psychotropic medications and the risk of fracture: A meta-analysis. Drug Saf 30 (2007) 171-184
127. Tennant Jr. F.S., Rawson R.A., Miranda L., and Obert J. Outpatient treatment of prescription opioid dependence: Comparison of two methods. NIDA Res Monogr 43 (1983) 315-321
128. Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD Clinical Practical Guidelines for the management of opioid therapy for chronic pain. Contract Number (2003) V101(93)P-1633(version 1.0)
129. Thomas J.A., Karver S., Cooney G.A., Chamberlain B.H., Watt C.K., Slatkin N.E., Stambler N., Kremer A.B., and Israel R.J. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 358 (2008) 2332-2343
130. Thomsen A.B., Becker N., and Eriksen J. Opioid rotation in chronic non-malignant pain patients: A retrospective study. Acta Anaesth Scand 43 (1999) 918-923
131. Toma M., McAlister F.A., Bialy L., Adams D.B., Vandermeer B., and Armstrong P.W. Transition from meeting abstract to full-length journal article for randomized controlled trials. JAMA 295 (2006) 1281-1287
132. Trescot A.M., Boswell M.V., Atluri S.L., Hansen H.C., Deer T.R., Abdi S., Jasper J.F., Singh V., Jordan A.E., Johnson B.W., Cicala R.S., Dunbar E.E., Helm II S., Varley K.G., Suchdev P.K., Swicegood J.R., Calodney A.K., Ogoke B.A., Minore W.S., and Manchikanti L. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 9 (2006) 1-39
133. United States General Accounting Office (GAO): Prescription drugs: State monitoring programs provide useful tool to reduce diversion. Report to the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives: May 17, 2002
134. van Tulder M., Furlan A.D., Bombardier C., and Bouter L. The Editorial Board of the Cochrane Collaboration Back Review Group: Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine 28 (2003) 1290-1299
135. van Tulder M.W., Vlaeyen J.W., Linton S.J., Morley S.J., and Assendelft W.J. Behavioral treatment for chronic low back pain. Cochrane Database of Syst Rev (2005) CD002014
136. Verhaak P.F., Kerssens J.J., Dekker J., Sorbi M.J., and Bensing J.M. Prevalence of chronic benign pain disorder among adults: A review of the literature. Pain 77 (1998) 231-239
137. Wasan A.D., Butler S.F., Budman S.H., Benoit C., Fernandez K., and Jamison R.N. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain 23 (2007) 307-315
138. Wastila L. The influence of multiple copy prescription programs on analgesic utilization. J Pharm Care Pain Symp Cont 4 (1996) 3-19
139. Webster L.R., Butera P.G., Moran L.V., Wu N., Burns L.H., and Friedmann N. Oxytrex minimizes physical dependence while providing effective analgesia: A randomized controlled trial in low back pain. J Pain 7 (2006) 937-946
140. Webster L., Jansen J.P., Peppin J., Lasko B., Irving G., Morlion B., Snidow J., Pierce A., Mortensen E., Kleoudis C., and Carteret E. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-included bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 137 (2008) 428-440
141. Webster L.R., and Webster R.M. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the Opioid Risk Tool. Pain Med 6 (2005) 432-442
142. Whiting P., Rutjes A., Reitsma J., Glas A., Bossuyt P., and Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 140 (2004) 189-202
143. Wiedemer N.L., Harden P.S., Arndt I.O., and Gallagher R.M. The opioid renewal clinic: A primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Med 8 (2007) 573-584
144. Wu S.M., Compton P., Bolus R., Schieffer B., Pham Q., Baria A., Van Vort W., Davis F., Shekelle P., and Naliboff B.D. The Addiction Behaviors Checklist: Validation of a new clinician-based measure of inappropriate opioid use in chronic pain. J Pain Symptom Manage 32 (2006) 342-351